

**Pioglitazone 15mg/metformin 850mg hydrochloride  
(Competact) (No. 252/06)**

---

**Takeda UK Ltd**

## Product Update

7 April 2006 (Issued August 2006)

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises the NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**pioglitazone 15mg/metformin 850mg hydrochloride (Competact)** is accepted for restricted use in NHSScotland for the treatment of type 2 diabetes mellitus. It should be used for overweight patients who are unable to achieve sufficient glycaemic control at their maximally tolerated doses of oral metformin alone. It is restricted to patients who cannot be treated with a sulphonylurea in combination with metformin. This combination product costs the same as equivalent doses of the individual constituent preparations and offers a more convenient, though less flexible, dosing regimen.

**Chairman  
Scottish Medicines Consortium**

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 18 July 2006.*